• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: hepatitis B DNA thresholds and risk of hepatocellular carcinoma: different number patterns in HBeAg-positive versus HBeAg-negative patients.

作者信息

Dusheiko Geoffrey

机构信息

University College London Medical School, Kings College Hospital, London, UK.

出版信息

Aliment Pharmacol Ther. 2020 Jun;51(12):1439-1440. doi: 10.1111/apt.15783.

DOI:10.1111/apt.15783
PMID:32445523
Abstract
摘要

相似文献

1
Editorial: hepatitis B DNA thresholds and risk of hepatocellular carcinoma: different number patterns in HBeAg-positive versus HBeAg-negative patients.社论：乙肝病毒DNA阈值与肝细胞癌风险：HBeAg阳性与HBeAg阴性患者的不同数值模式
Aliment Pharmacol Ther. 2020 Jun;51(12):1439-1440. doi: 10.1111/apt.15783.
2
Editorial: hepatitis B DNA thresholds and risk of hepatocellular carcinoma: different number patterns in HBeAg-positive versus HBeAg-negative patients. Authors' reply.
Aliment Pharmacol Ther. 2020 Jun;51(12):1440-1441. doi: 10.1111/apt.15794.
3
Intrahepatic distribution of hepatitis B virus antigens in patients with and without hepatocellular carcinoma.伴有和不伴有肝细胞癌的患者体内乙肝病毒抗原的肝内分布情况。
World J Gastroenterol. 2016 Mar 28;22(12):3404-11. doi: 10.3748/wjg.v22.i12.3404.
4
Hepatitis B e antigen and the risk of hepatocellular carcinoma.乙肝e抗原与肝细胞癌风险
N Engl J Med. 2002 Jul 18;347(3):168-74. doi: 10.1056/NEJMoa013215.
5
Letter: hepatitis B surface seroclearance does reduce the risk of hepatocellular carcinoma.
Aliment Pharmacol Ther. 2016 Jul;44(2):210-1. doi: 10.1111/apt.13674.
6
Letter: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance.
Aliment Pharmacol Ther. 2017 May;45(9):1286-1288. doi: 10.1111/apt.13983.
7
Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients.HBeAg阴性患者中与晚期肝病相关的乙肝病毒前S区缺失及复杂突变
Gastroenterology. 2007 Nov;133(5):1466-74. doi: 10.1053/j.gastro.2007.09.002. Epub 2007 Sep 6.
8
Performance of risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients.REACH-B 评分在 2012 年亚太肝脏研究学会（APASL）慢性乙型肝炎治疗指南下对慢性乙型肝炎患者治疗适应证分类中的肝细胞癌风险评估表现。
Aliment Pharmacol Ther. 2013 Jan;37(2):243-51. doi: 10.1111/apt.12144. Epub 2012 Nov 22.
9
Letter: risk of developing hepatocellular carcinoma in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation.信函：病毒载量高且谷丙转氨酶无显著升高的未经治疗的HBeAg阴性慢性乙型肝炎患者发生肝细胞癌的风险
Aliment Pharmacol Ther. 2019 Sep;50(5):618-619. doi: 10.1111/apt.15423.
10
Clinical, virologic and phylogenetic features of hepatitis B infection in Iranian patients.伊朗患者乙型肝炎感染的临床、病毒学和系统发育特征
World J Gastroenterol. 2008 Sep 21;14(35):5448-53. doi: 10.3748/wjg.14.5448.

引用本文的文献

1
Expanding antiviral therapy indications for HBeAg-negative chronic hepatitis B patients with normal ALT and positive HBV DNA.扩大对谷丙转氨酶（ALT）正常且乙肝病毒脱氧核糖核酸（HBV DNA）阳性的e抗原阴性慢性乙型肝炎患者的抗病毒治疗适应症。
Precis Clin Med. 2022 Nov 29;5(4):pbac030. doi: 10.1093/pcmedi/pbac030. eCollection 2022 Dec.